Synthesis of 1,2,4-Oxadiazin-5(6 H)-One Derivatives and Their Biological Investigation as Monoamine Oxidase Inhibitors
- PMID: 39683710
- PMCID: PMC11643077
- DOI: 10.3390/molecules29235550
Synthesis of 1,2,4-Oxadiazin-5(6 H)-One Derivatives and Their Biological Investigation as Monoamine Oxidase Inhibitors
Abstract
Monoamine oxidase (MAO) plays a key role in the pathogenesis of central nervous system disorders, and MAO inhibitors have been used in the treatment of depression and Parkinson's disease. In the search for new classes of MAO inhibitors, the present study investigated a series of 1,2,4-oxadiazin-5(6H)-one derivatives. This study provides the first optimization of the reaction conditions for the condensation of amidoximes with alkyl 2-halocarboxylates to yield the desired 1,2,4-oxadiazin-5(6H)-ones. The results of the in vitro MAO inhibition studies showed that the 1,2,4-oxadiazin-5(6H)-ones were indeed inhibitors of human MAO with the most potent inhibition observed for 5f (IC50 = 0.900 µM) and 7c (IC50 = 0.371 µM). It was concluded that, with appropriate substitution, 1,2,4-oxadiazin-5(6H)-one derivatives would act as good potency MAO-B inhibitors and lead compounds for the development of antiparkinsonian drugs. In Parkinson's disease, MAO-B inhibitors enhance central dopamine levels and reduce MAO-mediated production of hydrogen peroxide and resultant oxidative injury. This study represents one of few works to investigate synthetic approaches and biological activities of the 1,2,4-oxadiazin-5(6H)-one class of heterocycles.
Keywords: MAO; Parkinson’s disease; inhibition; monoamine oxidase; oxadiazine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.Eur J Med Chem. 2017 Apr 21;130:365-378. doi: 10.1016/j.ejmech.2017.02.059. Epub 2017 Mar 1. Eur J Med Chem. 2017. PMID: 28273563
-
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.Bioorg Med Chem. 2018 Nov 1;26(20):5531-5537. doi: 10.1016/j.bmc.2018.09.032. Epub 2018 Sep 25. Bioorg Med Chem. 2018. PMID: 30279044
-
Investigation of pyrazolo[1,5-a]quinoxalin-4-ones as novel monoamine oxidase inhibitors.Bioorg Chem. 2021 Mar;108:104563. doi: 10.1016/j.bioorg.2020.104563. Epub 2020 Dec 15. Bioorg Chem. 2021. PMID: 33376014
-
Recent Advancements and SAR Studies of Synthetic Coumarins as MAO-B Inhibitors: An Updated Review.Mini Rev Med Chem. 2024;24(20):1834-1846. doi: 10.2174/0113895575290599240503080025. Mini Rev Med Chem. 2024. PMID: 38778598 Review.
-
Parkinson's Disease: Unravelling the Medicinal Perspectives and Recent Developments of Heterocyclic Monoamine Oxidase-B Inhibitors.CNS Neurol Disord Drug Targets. 2025;24(4):263-284. doi: 10.2174/0118715273340983241018095529. CNS Neurol Disord Drug Targets. 2025. PMID: 39501950 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources